Navigation Links
Bayer Expands Its Hemophilia Leadership Development Program
Date:2/2/2012

WAYNE, N.J., Feb. 2, 2012 /PRNewswire/ -- To further its commitment to the hemophilia community, Bayer HealthCare is expanding the Bayer Hemophilia Leadership Development Program (BHLDP) by adding a community element to the internship experience.  The 2012 interns selected to participate in this prestigious program will spend five weeks of the eight-week program at a local hemophilia organization. 

The company is currently seeking applicants who are attending college and have been touched by hemophilia.  Those interested have until Monday, March 12th to apply for the program, which runs from June 18th-August 9th.  Participating interns will engage in leadership training, hands-on business projects, marketing and communications strategies, and help support the local hemophilia community.  Additional details and the application can be found at www.livingbeyondhemophilia.com/intern.

Of the many organizations that applied to participate, four chapters were chosen to mentor and manage an intern.  They are the Arizona Hemophilia Association, Bleeding Disorders Alliance Illinois, Hemophilia Foundation of Upstate New York – Rochester and Texas Central Hemophilia Association.

"Bayer is proud to offer this program, which is unique in the hemophilia community," said Leslie Donato, Vice President/General Manager, Hematology, Bayer HealthCare.  "It's dedicated to creating future hemophilia leaders through hands-on experience and collaboration with local chapter personnel and Bayer colleagues."

The 2012 program begins with a two-week orientation at Bayer HealthCare's U.S. headquarters in Wayne, NJ, where the interns will receive training on communications, problem solving and leadership skills as well as work with people in a number of departments to gain insights into how various parts of the company operate.  Interns will spend the following five weeks at the selected hemophilia organization, where they will gain first-hand knowledge about the work done on a local level and engage in projects building on the skills developed earlier in the program.  During the final week at Bayer, the interns will report on their experience and present a project developed with their local chapter. 

"We are very pleased that Bayer chose our chapter to participate in the newly expanded Hemophilia Leadership Development Program," said Tom Wilmarth, executive director of Hemophilia Foundation of Upstate New York – Rochester.  "We're confident our intern will gain valuable knowledge and fulfillment by supporting the hemophilia community in this way."

Bayer established the Hemophilia Leadership Development Program in 2007.  Since that time, many program participants have become more active hemophilia advocates and have gone on to careers serving the community, government and industry.    

About Hemophilia A
Hemophilia A, also known as factor VIII deficiency or classic hemophilia, is largely an inherited bleeding disorder in which one of the proteins needed to form blood clots in the body is missing or reduced. Hemophilia A, the most common type of hemophilia, is caused by deficient or defective blood coagulation proteins, known as factor VIII. Hemophilia A is characterized by prolonged or spontaneous bleeding, especially into the muscles, joints, or internal organs.  Approximately one in 5,000 males born in the United States has hemophilia.

About Bayer HealthCare Pharmaceuticals Inc.

Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals business of Bayer HealthCare LLC, a subsidiary of Bayer AG. Bayer HealthCare is one of the world's leading, innovative companies in the healthcare and medical products industry, and combines the activities of the Animal Health, Consumer Care, Medical Care, and Pharmaceuticals divisions.  As a specialty pharmaceutical company, Bayer HealthCare provides products for General Medicine, Hematology, Neurology, Oncology and Women's Healthcare.  The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases.

Forward-looking Statements
This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

BAYER and the Bayer Cross are registered trademarks of Bayer. 

 

 

 

 


'/>"/>
SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Phase III Data Show Bayers Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Thera
2. Phase 3 Data Show Bayers Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Therapi
3. Ventana Medical Systems, Inc. to Collaborate with Bayer on Companion Diagnostic Test for New Biological Cancer Therapy
4. Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI): Phase III Data on Bayers Investigational Compound Regorafenib (BAY 73-4506) in Patients with Metastatic Colorectal Cancer to be Presented as Late Breaking Or
5. Intendis, Inc. Changes Name to Bayer HealthCare
6. Bayers Xarelto® (rivaroxaban) Becomes First Fixed Dose Once-Daily Anticoagulant Tablet Approved in the UK for Stroke Prevention in non-valvular Atrial Fibrillation; and the First Single Drug Regimen for Deep Vein Thrombosis
7. Bayers Drospirenone-containing Combination Oral Contraceptives: FDA Advisory Committees Affirm Positive Benefit-risk Profile and Recommend an Update of Labels to Reflect Information From Available Studies
8. Bayer HealthCare LLC Stops Trademark Infringement by Indian Pharmaceutical Company
9. Bayer HealthCare and Health Alliance Medical Plans Enter Outcomes-based Agreement
10. Bayer HealthCares MEDRAD and Nuance Communications Unveil Industrys First(1) Solution to Automate CT Contrast-Injection Documentation at the annual Radiology Society of North America (RSNA) Meeting
11. Intergraph® Technology Enables Bayer Technology Services to Engineer New Plant in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... May 4, 2016  It,s time for an upgrade. There are many medical recorders ... 3.5 inch LCD, the illustrious DVMAXX HD  offers unparalleled connectivity and functionality.  Ampronix ... a world class manufacturer of innovative technology.  Photo - http://photos.prnewswire.com/prnh/20160503/363416 ... ... ...
(Date:5/4/2016)... 2016 Valeritas Holdings, Inc. (OTCQB: ... public offering (APO). This was accomplished via a reverse ... and a private placement of approximately 5 million shares ... Under the terms of the reverse merger, ... Inc. will trade on the OTC Markets under the ...
(Date:5/4/2016)... Research and Markets has ... lymphocytic Leukemia Market and Competitive Landscape Highlights ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... and Competitive Landscape Highlights 2016, provides comprehensive ... Acute Lymphocytic Leukemia epidemiology, Acute Lymphocytic Leukemia ...
Breaking Medicine Technology:
(Date:5/4/2016)... , ... May 04, 2016 , ... Level 10 Head ... her verbal commitment to the University of Arizona for the fall of 2019. ... decision last month. Brovedani’s commitment to the GymCats came from her connection with the ...
(Date:5/4/2016)... ... ... The Spiritual Care Association (SCA) has declared May 10, 2016 ... and their families, and their overall contribution to the health care system. It will ... sent “Thank You Chaplain” cards with hand-painted artwork to about 10,000 chaplains and pastoral ...
(Date:5/4/2016)... ... May 04, 2016 , ... All-Star Insurance of ... assist the people of their local community. The agency pledges to select a ... Their hope is to bring awareness to important local causes with fundraising and ...
(Date:5/4/2016)... ... May 04, 2016 , ... Momsense, Inc. ... The company’s patented technology, The Smart Breastfeeding Meter, is designed to monitor and ... technology is now available for purchase at Target.com . , Breastfeeding ...
(Date:5/4/2016)... Plainsboro, NJ (PRWEB) , ... May 04, 2016 ... ... for pharmacists and the pharmacy industry, today announced that it was chosen as ... Purchasing Alliance (APPA) Industry Awards . The awards acknowledge the hard work and ...
Breaking Medicine News(10 mins):